American Society for Radiation Oncology Annual Meeting 2026

Description

+ Include:  videos + file sub vtt +  pdf, size:  GB

+ Target Audience: radiation oncologists, medical oncologists, radiation oncology residents, radiation biologists, radiation physicists, dosimetrists, oncologists

+ Sample video: contact me for sample video

+ Information:

• Meeting Title: 2026 ASTRO Annual Meeting & 2026 ASTRO Annual Meeting onDemand

• Organizer: American Society for Radiation Oncology (ASTRO)

• Overarching Theme: “Data to Dialogue: Communicating Radiotherapy’s Value to Advance Care”

• Dates & Location: Saturday, September 26 – Wednesday, September 30, 2026 at the Thomas M. Menino Convention & Exhibition Center, Boston, Massachusetts, USA

• Description: Led by ASTRO President Neha Vapiwala, MD, FASTRO, the 2026 ASTRO Annual Meeting brings together radiation oncologists, physicists, radiation therapists, clinicians, scientists, patient advocates, and researchers across all oncologic disciplines to exchange ideas and promote multidisciplinary cancer care. Centered on the theme “Data to Dialogue: Communicating Radiotherapy’s Value to Advance Care,” the program elevates clinical trials, patient perspectives, patient-reported outcomes, value-driven quality and safety, healthcare access, and professional development. Scientific and educational sessions—including the Presidential Symposium, Keynote Lectures, Plenary Session, Clinical Trials, Cancer Breakthroughs, Practical Radiation Oncology (PRO) tracks, Workshops, International Sessions, Education Sessions, Scientific Sessions, Quick Pitch Sessions, and Science Highlights—span breast, central nervous system, gastrointestinal, genitourinary, gynecological, head and neck, hematologic/lymphoma, musculoskeletal, sarcoma, cutaneous, pediatric, and thoracic malignancies, as well as benign/functional conditions, radiopharmaceutical therapy, brachytherapy, adaptive radiotherapy, artificial intelligence, radiation biology, and medical physics

Learning Objectives

At the conclusion of this activity, the learner will be able to:

• Implement the advances in radiation oncology technology and practice that help improve patient outcomes and quality of life.

• Employ quality and safety measures in the delivery of radiation therapy.

• Develop a broad understanding of all cancer treatments available to patients.

• Demonstrate ways to incorporate a person-centered approach in providing patient care.

• Discuss factors that cause disparities and inequities in radiation oncology and develop strategies to address and improve equitable access and care.

Target Audience

This continuing medical education activity is designed to meet the interests of radiation oncologists, medical oncologists, radiation oncology residents, radiation biologists, radiation physicists, dosimetrists, oncologists working in related specialties, radiation therapists, radiation oncology nurses, radiation oncology administrators, diagnostic radiologists and all other health professionals involved in the field of radiation oncology.

Best for Radiation Oncologists, Medical Oncologists, Surgical Oncologists, Diagnostic Radiologists, Nuclear Medicine Physicians, Radiopharmaceutical Therapy Specialists, Breast Oncologists, Breast Surgeons, Plastic and Reconstructive Surgeons, Thoracic Oncologists, Pulmonologists, Thoracic Surgeons, Neuro-Oncologists, Neurosurgeons, Neurologists, Neuroradiologists, Spine Surgeons, Orthopedic Oncologists, Musculoskeletal Specialists, Gastroenterologists, Hepatologists, Colorectal Surgeons, Hepatopancreatobiliary Surgeons, Urologic Oncologists, Urologists, Gynecologic Oncologists, Obstetricians and Gynecologists (OB-GYNs), Reproductive Endocrinologists and Infertility Specialists, Otolaryngologists – Head and Neck Surgeons, Oral and Maxillofacial Surgeons, Hematologists, Hematologic Oncologists, Pediatric Oncologists, Dermatologists, Cutaneous Oncologists, Hospice and Palliative Medicine Specialists, Geriatric Oncologists, Geriatricians, Endocrinologists, Rheumatologists, Medical Geneticists, Molecular Pathologists, and Clinical Informatics Specialists.

Topics

Saturday, September 26, 2026

• 7:55 am | PRO 01: Anticipating and Reducing Potential Toxicity in Breast Cancer Treatment: Hypofractionation and Volume Reduction, Planning Objectives and Techniques to Limit Toxicity, and Management of Adverse Effects

• 8:00 am | WKSHP 01: Physics Insights for Advanced Clinical Practice: Adaptive, Re-irradiation, AI and Trials

• 9:00 am | WKSHP 02: Functional Radiation Medicine Workshop

• 9:15 am | PRO 02: Practical Tips for Optimizing Your Radiopharmaceutical Therapy Program

• 10:00 am | WKSHP 03: Brachytherapy Didactic Session – General Attendees (Part I)

• 10:45 am | PRO 03: Practical Management of NSCLC in the Immunotherapy Era

• 1:00 pm | WKSHP 05: ACGME Workshop: Review Committee Update and Accreditation Info You Need for Your Program

• 1:00 pm | WKSHP 06: Implementing Best Practices for Clinical, Operations and Research Care in a Radiopharmaceutical Therapy Program

• 1:00 pm | PRO 04: Oral Cavity Cancer in Clinical Practice: Multimodality Care and Toxicity Management

• 2:15 pm | PRO 05: CTVs, PTVs and PRVs Oh My! Margins (or perhaps not) in Modern CNS Radiation

• 3:45 pm | PRO 06: People and Software: Tools that Make Clinic, Treatment Planning and Delivery More Efficient

• 5:00 pm | PRO 07: Management of Melanoma and Merkel Cell Carcinoma: Immunotherapy and Its Impact on Radiation Decision Making

Sunday, September 27, 2026

• 8:20 am | PS 01: Presidential Symposium – Data to Dialogue: Communicating Radiotherapy’s Value to Advance Care – Session I: Organ-Preservation: The Undersung Value of RT

• 9:40 am | PS 02: Presidential Symposium – Data to Dialogue: Communicating Radiotherapy’s Value to Advance Care – Session II: Challenges and Opportunities in Scientific Knowledge Creation and Dissemination

• 10:30 am | PS 03: Presidential Symposium – Data to Dialogue: Communicating Radiotherapy’s Value to Advance Care – Session III: Patients’ Perceptions of Radiation Therapy

• 11:00 am | PS 04 I: Presidential Symposium – Data to Dialogue: Communicating Radiotherapy’s Value to Advance Care – Session IV: Stakeholder Perspectives Panel I

• 11:30 am | PS 04 II: Presidential Symposium – Data to Dialogue: Communicating Radiotherapy’s Value to Advance Care – Session IV: Stakeholder Perspectives Panel II

• 1:25 pm | PRO 08: The Continued Need of Radiation Therapy in Rectal Cancer: From Early to Late Stage Disease

• 1:30 pm | CT 01: Clinical Trials

• 2:30 pm | WKSHP 07: When Disaster Strikes: Safeguarding Radiotherapy’s Value and Continuity Across Catastrophic Events

• 2:45 pm | PRO 09: Key Policy Issues Impacting Radiation Oncology

• 3:00 pm | EDU 01: Artificial Intelligence, Robotics and Emerging Technologies in Gynecologic Radiation Oncology: From Automation to Precision Delivery

• 3:00 pm | EDU 02: Challenging Cases in Lung Stereotactic Radiotherapy

• 3:00 pm | EDU 03: Nonoperative and Preoperative Local Management of Breast Cancer: From Data to Shared Decisions

• 3:00 pm | EDU 04: Breathing Motion Management in 2026: Recommendations From AAPM Task Group 324, Updated Guidance on the Management of Respiratory Motion in Radiation Oncology

• 3:00 pm | INT 01: Radiotherapy Under Debate: Defending the Indication in Latin America Through Evidence, Value, and Access (Session in Spanish)

• 3:00 pm | QP 01: Multidimensional Toxicity in Breast Cancer Radiotherapy: Integrating Clinical, Patient-Reported, and Biological Outcomes

• 3:00 pm | QP 02: Advances in Pediatric Radiotherapy and Side Effect Mitigation

• 3:00 pm | SS 01: Reading the Whole Patient: Faces, Genes, Images, and the Future of Predictive AI

• 3:00 pm | SS 02: Escalate, De-escalate, or Substitute? Trials Shaping Prostate Cancer Care

• 3:00 pm | SS 03: Technologically Driven Strategies in HPV-Related OPSCC

• 3:00 pm | SS 04: Medical Education/Professional Development Oral Abstract Session

• 3:00 pm | SS 05: Advances in Radiation Response and Microenvironment

• 3:15 pm | INT 02: ASTRO/ESTRO Session: Adoption of AI Tools and Technologies: Present and Future Impact on Clinical Care Delivery

• 3:45 pm | PRO 10: Prostate SBRT 2.0: Refining Indications, Optimizing Outcomes

• 4:45 pm | PRO 11: Making Sense of Clinical Trials in Community Radiation Oncology: From Headlines to High-Value Care

• 5:00 pm | EDU 05: Radiotherapy Treatment Planning for Anal Cancer: Personalized Radiation and Modern Techniques

• 5:00 pm | EDU 06: Diagnosis to Decision: Distinguishing and Managing Radiation Necrosis vs. Recurrent Brain Metastases

• 5:00 pm | EDU 07: Beyond the Bone: Difficult Cases that Stretch the Definitions of Palliative Radiotherapy

• 5:00 pm | EDU 08: Biomarkers to Predict Radiation Treatment Toxicity

• 5:00 pm | EDU 09: Communicating the Value and Risks of Low-Dose Radiotherapy for Benign Conditions: From Guidelines and Risk Models to Multidisciplinary Conversations with Patients and Referrers

• 5:00 pm | EDU 10: The Growing Role and Opportunities for Nurses and Advanced Practitioners in Radiation Oncology

• 5:00 pm | QP 04: Lung Quick Pitch: Early Stage NSCLC and Limited Stage SCLC

• 5:00 pm | QP 15: Boston Heme Party: Bite-Sized Breakthroughs

• 5:00 pm | SS 08: Kidneys, Bladders, and Breakthroughs

• 5:00 pm | SS 09: From Trials to Real-World Impact

• 5:00 pm | SS 10: AI Applications in Imaging Analysis and Segmentation

Monday, September 28, 2026

• 8:00 am | EDU 11: Challenging Cases in Pediatric/AYA Sarcomas: Contemporary Approaches and Novel Technologies (SBRT/PULSAR, GRID/SFRT, Adaptive Radiotherapy)

• 8:00 am | EDU 12: Measuring and Communicating the Value of Radiation Oncology

• 8:00 am | EDU 13: Mechanistic and Clinical Analysis of Tumor Treating Fields

• 8:00 am | EDU 14: Gen X Cancers: The Rising Incidence and Challenges in Management for Patients Diagnosed With Cancer in Their 40s and 50s

• 8:00 am | EDU 15: Management of Sarcoma in Patients with Cancer Predisposition Syndromes

• 8:00 am | EDU 16: Strategies for Managing Head/Neck Cancer for the Frail or Elderly Patient

• 8:00 am | EDU 17: Spatially Fractionated Radiation Therapy (SFRT): Biological Mechanisms and Clinical Translation

• 8:00 am | QP 05: Predicting Outcomes in Breast Cancer: From Multi-Omics to AI-Driven Models

• 8:00 am | QP 06: Neurocognition and Novel Therapies in Glioma

• 8:00 am | QP 07: Predicting, Protecting, Preserving, and Pushing Dose in Rectal Cancer

• 8:00 am | SS 11: Interventions to Advance Healthcare Access in Radiation Oncology

• 8:00 am | SS 12: Small Cell Lung Cancer and Thymic Malignancies

• 8:00 am | SS 13: AI Applications In Outcome Prediction

• 8:30 am | UPDATE 02: Key Policy Issues Impacting Radiation Oncology – General Session

• 9:15 am | Keynote 01: Keynote I

• 10:45 am | EDU 18: Integrating Postmastectomy Radiotherapy (PMRT) with Breast Reconstruction: Insights from Plastic Reconstructive Surgery and the Role of the Radiation Oncologist

• 10:45 am | EDU 19: ASTRO GU Guideline Session: Radiation Therapy for Bladder Cancer and Localized Prostate Cancer: A Case-Based Interactive Discussion

• 10:45 am | EDU 20: Updates and Innovations in Multi-Disciplinary Metastatic Spine Oncology

• 10:45 am | EDU 21: Improving Communication to Enhance Patient Care in the Palliative Setting

• 10:45 am | EDU 22: Endometrial and Cervical Cancer Case Discussion on Utilizing Molecular Data for Treatment Decisions

• 10:45 am | EDU 23: Functional Imaging Guided Radiation Therapy: Current Status and Future Directions

• 10:45 am | EDU 24: Comprehensive eContouring for GI, Head and Neck and Thoracic Cancers

• 10:45 am | SS 14: Now Is a STELLAR Time to TORCH Colorectal Cancer

• 10:45 am | SS 15: Immunotherapy Integration and Immuno Biomarkers Across Mucosal and Cutaneous SCC

• 10:45 am | SS 16: Early Stage and Locally Advanced NSCLC

• 10:45 am | SS 17: Emerging Data for Use of Radiotherapy in Nonmalignant Conditions

• 10:45 am | SS 18: Patient Reported Outcomes/QoL/Survivorship Oral Session

• 10:45 am | SS 19: BEST of Physics

• 10:45 am | SS 22: Some crHEME With Your Coffee? A Winning Blend of Radiation and Systemic Therapy in Hematologic Malignancies

• 1:00 pm | PRES ADD: ASTRO Presidential Address

• 1:30 pm | PL 01: Plenary Session

• 3:00 pm | EDU 25: Closing the Safety Loop: Translating RO-ILS Lessons Into Practical QA Safeguards, Workflow Guardrails and Safer Software

• 3:00 pm | EDU 26: At a Crossroads: A Multidisciplinary Perspective on the Management of Esophageal Adenocarcinoma

• 3:00 pm | EDU 27: Fertility Preservation and Family Building Across Cancer Care: Practical Strategies for Diverse Patient Needs

• 3:00 pm | EDU 28: Redefining Care for Thoracic Neuroendocrine Tumors: A Multidisciplinary Update

• 3:00 pm | EDU 29: Developing, Activating and Operating Clinical Trials

• 3:00 pm | EDU 30: Reinvigorating and Expanding the Role for Radiotherapy for Hematological Malignancies of the Central Nervous System

• 3:00 pm | INT 03: Global SFRT Practice: Mapping Evidence Gaps for Successful Clinical Implementation

• 3:00 pm | QP 08: CNS Metastases and LMD: Patient Selection, Treatment Strategy and Outcomes

• 3:00 pm | QP 09: Fewer Fractions, Greater Precision: Innovations in Prostate SBRT

• 3:00 pm | QP 10: Maximizing Therapeutic Techniques in Virally Driven Head and Neck Cancer

• 3:00 pm | QP 11: Adaptive Radiation Therapy

• 3:00 pm | QP 13: Pixels to Plans: AI-Driven Contouring and Imaging Innovation

• 3:00 pm | SS 21: Immuno-Radiotherapy and Liquid Biomarkers in Gynecologic Cancer: Toward Precision Care

• 3:00 pm | SS 23: Emerging Pathways and Targeted Therapies

• 3:00 pm | SS 24: Innovations in Rare Cutaneous and Soft Tissue Malignancies

• 5:00 pm | EDU 31: Therapeutic Updates for Rare Genetically Linked Childhood Tumors: ATRT and Malignant Rhabdoid Tumors

• 5:00 pm | EDU 32: Data to Dialogue: Techniques and Outcomes for Optimizing Microboosting in Prostate Cancer

• 5:00 pm | EDU 33: Evolving Paradigms in Axillary Nodal Management: Precision Medicine Refining Regional Breast Cancer Care

• 5:00 pm | EDU 34: Generative AI in Radiation Oncology: Moving from Hype to Clinical Implementation

• 5:00 pm | EDU 35: Biological Insights Into Selection of Specific HPV+ Oropharyngeal Cancer Patients Appropriate for Radiation Dose De-escalation

• 5:00 pm | EDU 36: Physics Considerations for RPT Clinical Trials: Identifying Barriers, Evaluating Institutional Readiness and Defining Oversight Frameworks

• 5:00 pm | QP 12: Molecular Biomarkers and Precision Oncology in CNS Tumors

• 5:00 pm | QP 14: Modernizing Definitive Therapy in Cervical Cancer: From Systemic Intensification to Adaptive Radiation

• 5:00 pm | QP 16: Lung Quick Pitch: Locally Advanced NSCLC

• 5:00 pm | QP 17: Palliative Care Quick Pitch

• 5:00 pm | QP 18: Novel Delivery and QA

• 5:00 pm | QP 22: Refining Prostate Cancer Care: Integration, Innovation, and Outcomes

• 5:00 pm | SS 07: Don’t Get Squeamish About Squams of the GI Tract!

• 5:00 pm | SS 25: From Assessing Gaps to Treatment Delivery: Scaling Safe Radiotherapy in Resource-Limited Settings

Tuesday, September 29, 2026

• 8:00 am | CB 01: Cancer Breakthroughs Session: A Collaborative Review of the Year’s Most Impactful Studies

• 9:00 am | Keynote 02: Keynote II

• 12:30 pm | EDU 37: ASTRO GI Guideline Session: Radiation Therapy for Gastric Cancer and Pancreatic Cancer: A Case-Based Interactive Discussion

• 12:30 pm | EDU 38: At the Margins: Navigating Challenging Vulvar and Vaginal Cancers

• 12:30 pm | EDU 39: Handling CNS Metastases in Sick Patients

• 12:30 pm | EDU 40: Liquid Biopsy: ctDNA in Early Stage and Metastatic Breast Cancer

• 12:30 pm | EDU 41: Harnessing the Microbiome in Low-Dose Radiation to Shape Tumor and Immune Responses

• 12:30 pm | EDU 42: Radiation Wins: New Evidence and Evolving Strategies in Multiple Myeloma

• 12:30 pm | INT 04: Challenges and Solutions of Implementing New Radiotherapy Advanced Techniques in LMICs

• 12:30 pm | QP 19: Research to Inform Healthcare Access Interventions in Radiation Oncology

• 12:30 pm | QP 20: Beyond Treatment: Innovations in Supportive Care Across the Radiation Oncology Continuum

• 12:30 pm | SS 27: Advances in Multimodal Therapy for Glioblastoma: From Phase I to Phase III Trials

• 12:30 pm | SS 28: From Data to Decisions: AI That Changes How We Treat Patients

• 12:30 pm | SS 29: Intensify, Shorten, or Personalize? Modern Approaches to Post-prostatectomy RT

• 12:30 pm | SS 30: Optimizing Therapy, Toxicity, and Supportive Care in Head & Neck Cancers

• 12:30 pm | SS 31: Mechanisms of Resistance and Normal Tissue Toxicity

• 12:30 pm | SS 32: Motion Management and Novel Onboard Imaging

• 12:30 pm | SS 42: Advanced Lung Cancer and Drug Combinations

• 2:00 pm | INT 05: Reirradiation in Radiation Oncology: A Latin American Perspective on Biology, Technology and Clinical Decision Making (Session in Spanish)

• 2:15 pm | EDU 43: Contemporary Management of High-Risk Cutaneous Squamous Cell Carcinoma: Evidence-Based Integration of Adjuvant Immunotherapy and Radiotherapy

• 2:15 pm | EDU 44: Claims-Based Research in Radiation Oncology: Emerging Methods and Contemporary Results

• 2:15 pm | EDU 45: Photon-Counting CT in Radiotherapy: From Imaging Innovation to Clinical Impact

• 2:15 pm | EDU 46: Perioperative Immunotherapy in Head and Neck Cancer: Trial Data, Real-World Practice and Radiation Oncology Implications

• 2:15 pm | INT 06: CT-Guided, MRI-Guided, or Offline Adaptive Radiation Therapy? A Structured, Case-Based Debate on Value, Efficiency and Use across Global Resource Settings

• 2:15 pm | LBA 01: Late-breaking Abstract Session

• 2:15 pm | SS 06: Musculoskeletal Tumors and Skeletomuscular Toxicities

• 2:15 pm | SS 33: Advances in the Treatment of Brain Metastases

• 2:15 pm | SS 34: The Automated Clinic: AI-Powered Contouring, Monitoring, and Data Extraction

• 2:15 pm | SS 35: Particles, Protection, and Priming in Pancreaticohepatobiliary Cancer

• 2:15 pm | SS 37: Radiation-Immune Crosstalk in Tumor and Normal Tissue Response

• 2:15 pm | SS 38: Imaging Biomarkers

• 2:15 pm | SS 44: Using AI and Other Software to Elevate Patient Safety and Quality

• 2:15 pm | WKSHP 08: Grant Writing Workshop

• 3:45 pm | EDU 47: Precision in Practice: The Use of Novel Biomarkers in GU Cancers

• 3:45 pm | EDU 48: Improving Disability Inclusion in Radiation Oncology, From Theory to Clinic

• 3:45 pm | EDU 49: Beyond the Nodes: A Practical Guide to Extranodal Lymphomas

• 3:45 pm | EDU 50: Establishing a National Quality Assurance Framework for Brachytherapy Trials: An Unmet Need

• 3:45 pm | EDU 51: Mythbusting Radiation Oncology: Communicating the Truth and Value of Radiotherapy to the Public, Patients, Providers and Policymakers

• 3:45 pm | INT 07: Challenges of Developing a Radiation Oncology Program in a LMIC Country: The Tale of Four Centers

• 3:45 pm | QP 03: Right Care, Right Cost: Access and Utilization in Oncology

• 3:45 pm | QP 21: Innovating With Software to Drive Patient Safety & Quality

• 3:45 pm | QP 23: Radiotherapy for Nonmalignant Conditions

• 3:45 pm | QP 24: Novel Delivery, Metabolism, and Immune Modulation

• 3:45 pm | SS 36: Predicting Benefit and Toxicity: Biomarkers in Prostate Radiotherapy

• 3:45 pm | SS 40: Evolving Paradigms in High-Risk Breast Cancer: Optimization and Integration of Treatment Modalities Across the Disease Continuum

• 3:45 pm | SS 41: Optimizing Radiation Therapy in Gynecologic Cancers: Fractionation, Targeting, and Toxicity Reduction

• 3:45 pm | SS 43: Palliative Care in Oncology

• 3:45 pm | SS 45: Novel Treatment and Safety

• 5:15 pm | EDU 52: The Challenges of Thoracic Reirradiation

• 5:15 pm | EDU 53: Rewriting Metastatic Biology With Radiotherapy: States, Immunity and CIN

• 5:15 pm | EDU 54: Equipping the Clinician for the Latest in Management of Challenging Gliomas

• 5:15 pm | EDU 55: Data to Dollars: A Radiation Oncologist’s Role in Advocating for the Financial Future of Our Patients and Our Field

• 5:15 pm | INT 08: ASTRO/CSCO Joint Session: AI-Enabled Radiation Therapy for Global Oncology: Practical Implementation for Cost Reduction

• 5:15 pm | QP 25: Clinical Potpourri: Navigating Early-Stage RT, N1mi Disease, and Risk Mitigation in Triple Negative and HER2+ Breast Cancer

• 5:15 pm | QP 26: The Right Patient, the Right Treatment: Machine Learning for Stratification and Prediction

• 5:15 pm | QP 27: Getting SMART About Ablative Radiation Therapy in Pancreaticobiliary Cancer and Liver Metastases

• 5:15 pm | QP 28: Actionable Biomarkers: Guiding Therapy Selection and De-escalation

• 5:15 pm | QP 29: Response Assessment and Risk Stratification in Gynecologic Cancers: Biomarkers, Imaging, and Outcomes

• 5:15 pm | QP 30: HPV-associated Oropharyngeal Cancer (HPVOPC): De-escalation, Volumes, and Outcomes

• 5:15 pm | QP 31: Medical Education/Professional Development Quick Pitch

• 5:15 pm | QP 32: Patient Reported Outcomes/QoL/Survivorship Quick Pitch

• 5:15 pm | QP 33: Advances in Planning Algorithm and Optimization

• 5:15 pm | QP 34: Skin and Sarcoma Shorts: Clinical Highlights and Recent Advances

Wednesday, September 30, 2026

• 8:00 am | EDU 56: Challenging Cases: The Evolving Role of Radiation Therapy for Rare Genitourinary Cancers

• 8:00 am | EDU 57: The Biology of Radiopharmaceuticals (RPTs): Beyond the Physical Properties

• 8:00 am | EDU 58: Auto-Planning in the Wild: Lessons Learned from Clinical Deployment

• 8:00 am | QP 35: Digital Allies: AI Tools Built for the Real Clinical Environment

• 8:00 am | QP 36: From Brachy to Beams to Biologics: Innovations in Esophageal and Liver Cancer

• 8:00 am | QP 37: From Detection to Re-treatment: Managing Radiorecurrent Prostate Cancer

• 8:00 am | QP 38: Lung Quick Pitch: Oligometastatic and Oligoprogressive NSCLC

• 8:00 am | QP 39: Imaging for Positioning and Motion Management

• 8:00 am | SH 01: Breast Cancer – Science Highlights

• 8:00 am | SH 02: Central Nervous System – Science Highlights

• 8:00 am | SH 03: Digital Health Innovation and Informatics – Science Highlights

• 8:00 am | SH 04: Gastrointestinal Cancer – Science Highlights

• 8:00 am | SH 05: Genitourinary Cancer – Science Highlights

• 9:15 am | QP 40: Personalized Therapy and Special Populations in Head and Neck Cancer

• 9:15 am | QP 41: Biologic Determinants of Radiation Response

• 9:15 am | QP 42: Imaging-Derived Outcome Prediction

• 9:15 am | QP 47: Research Highlights From Around the Globe

• 9:15 am | SH 06: Gynecological Cancer – Science Highlights

• 9:15 am | SH 08: Hematologic Malignancies – Science Highlights

• 9:15 am | SH 09: Lung Cancer/Thoracic Malignancies – Science Highlights

• 9:15 am | SS 46: Right-Sizing Radiation in Early Breast Cancer: Omission, Shortening, and Targeted Approaches

• 9:15 am | SS 47: Spine SBRT: Risk, Safety, and Outcomes

• 9:15 am | SS 48: Beyond Tumor Control: Quality of Life and Toxicity in Prostate RT

• 9:15 am | SS 49: Smart Planning and Adaptation

• 10:45 am | QP 43: Treatment Strategies in Localized and Advanced Prostate Cancer

• 10:45 am | QP 44: Biology and Prevention of Radiation-Induced Injury

• 10:45 am | QP 45: AI Powered Dose Prediction and Segmentation

• 10:45 am | QP 46: Imaging for Planning

• 10:45 am | SH 07: Head and Neck Cancer – Science Highlights

• 10:45 am | SH 11: Pediatric Cancer – Science Highlights

• 10:45 am | SH 12: Sarcoma and Cutaneous Tumors – Science Highlights